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Abstract
Background: In the absence of an adult vaccination register, coverage estimates for influenza and pneumococcal
vaccination come from surveys and other data sources.
Methods: Systematic review and meta-analysis of studies examining vaccination coverage in Australian adults from
1990 to 2015, focusing on groups funded under the National Immunisation Program, and intervals prior to and
following the introduction of universal funding.
Results: Twenty-two studies met the inclusion criteria; 18 used self-report to determine vaccination status. There
were 130 unique estimates of coverage extracted. Among adults aged ≥65y, during the period of universal funding
(1999-onwards), the summary estimate of annual influenza vaccination coverage from 27 point estimates was 74.8 %
(95 % CI 73.4–76.2 %; range 63.9–82.4 %); prior to this period (1992–1998) from 10 point estimates it was 61.3 % (95 %
CI 58.0–64.6 %; range 44.3–71.3 %). For the period of universal funding for pneumococcal vaccination (2005-onwards)
the summary estimate for coverage was 56.0 % (95 % CI 53.2–58.8 %; range 51.2–72.8 %, 10 point estimates); prior to
2005 it was 35.4 % (95 % CI 18.8–52.0 %; range 15.4–45.2 %). Coverage for both vaccines was significantly higher
following the introduction of universal funding. Influenza vaccination coverage in those aged 18–65 years with a
medical indication was lower but data were not combined. Seven studies reported on Aboriginal Australians with
three studies reporting five coverage estimates for influenza vaccination in adults ≥65 years (range 71 % - 89 %).
Conclusions: Adult influenza and pneumococcal vaccination coverage has increased since the introduction of
universal funding, but remains sub-optimal, with pneumococcal coverage lower than influenza. Implications: This
review highlights the need for more coverage data overall and in high risk groups, to support public health programs
to improve coverage.
Background
Vaccination is a key public health strategy to mitigate
the impact of some important infectious diseases [1].
In Australia, vaccines are funded nationally for children
and adults under the Australian National Immunisation
Program (NIP), as well being available privately. Over the
last 20 years, as new vaccines and evidence supporting
their effectiveness have become available, the NIP has
undergone a number of changes. For adults, annual
influenza vaccination has been funded nationally since
1999 for all those aged ≥65 years and, since 2010, for
those less than 65 years of age who are at higher risk of
infection, such as people with circulatory and respiratory
conditions and pregnant women [2, 3]. All Aboriginal and
Torres Strait Islander people aged over 15 years have also
been funded for influenza vaccination since 2010.
Pneumococcal vaccination has been funded for all adults
aged ≥65 years and all Aboriginal and Torres Strait
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Islander adults aged ≥50 years since 2005 [2]. It is also
funded for Aboriginal and Torres Strait Islander adults
aged from 15 to 49 years who have medical conditions that
increase their risk of invasive pneumococcal disease [4].
An important measure of vaccine program success is
coverage. While childhood vaccination coverage can be
monitored by the Australian Childhood Immunisation
Register [5] and the recently established human papilloma-
virus (HPV) vaccination program register collects compre-
hensive data on HPV vaccine provided to adolescents [6],
at the time of publication of this review, no national regis-
ter to document vaccination of older adults existed, al-
though some states have adult registers. Therefore, we
conducted a systematic search and analysis of the available
evidence to quantify levels of influenza and pneumococcal
vaccination coverage reported in adults in Australia, the
methods used to measure coverage in these studies, and
whether studies reported on other factors associated with
influenza and pneumococcal vaccination, such as Aborigi-
nality or medical indications.
Methods
Search strategy and terms
This review was developed in line with the PRISMA guide-
lines [7]. Electronic searches of MEDLINE, the Cochrane
Library and EMBASE were conducted to identify relevant
journal articles published between 1 Jan 1990 and 31 May
2015. The search terms and strategy used were as follows:
“vaccination” or “immunisation” AND “influenza” or
“pneumococcal” AND “coverage” or “uptake” or “rate”
AND “adult” AND “Australia”. For grey literature, such as
government reports, a Google and Google Scholar search
was conducted using the search terms; “adult” AND “vac-
cination” AND “coverage” AND “Australia”. Reference lists
of review articles were scanned for relevant publications
and experts in the field were also consulted.
All titles and abstracts or executive summaries found
through the search strategy were screened (AD) to
determine if they were relevant to the review. The full text
of those articles that appeared to meet the inclusion criteria
were retrieved and reviewed for relevance. Where there
was uncertainty the report was reviewed by a co-author.
Inclusion/Exclusion criteria
Studies were included if they met the following criteria:
reported vaccination coverage for influenza, or pneumo-
coccal disease in adults (defined as ≥18 years); were
published between January 1990 and May 2015; and
involved an Australian population defined only by geo-
graphic area and age group. Studies were excluded if they:
only described vaccination in a specific population such as
healthcare workers, military personnel, pregnant women,
and the work place. As a systematic review of pandemic
H1N1 influenza vaccination coverage has already been
published [8], studies examining this vaccine alone were
excluded. No language restrictions were imposed.
Data extraction and synthesis
A standard data extraction form was used and two authors
(AD and SK) independently extracted data. The data
extracted from each study included: article ID; study design
including sampling strategy; sample size; time period; study
population (e.g. location, age); method of vaccination status
ascertainment, reported influenza and pneumococcal vac-
cination coverage, any factors reported to be associated
with vaccination. Where it was missing or unclear, authors
or organisations were contacted to obtain additional data.
Data extracted from each study were tabulated. They
were then grouped according to the infection the vaccine
prevented (seasonal influenza strains or S pneumoniae) and
also by age group (≥65 years, <65 years). As the lower age
bound sampled varied between studies, for convenience, the
younger adult age group is referred to as <65 years. Data
from studies reporting influenza coverage specifically in
adults aged <65 years with risk factors for complications
and serious disease following influenza infection (i.e. those
funded for influenza vaccination from 2010) was shown
separately. Also studies reporting influenza and/or pneumo-
coccal vaccination specifically in Aboriginal and Torres
Strait Islander adults were shown separately.
For estimates of vaccination coverage, to preserve indi-
vidual survey sampling designs, we used the point esti-
mates and the standard error of the proportion provided
by the study. Where 95 % confidence intervals (CIs) but
not standard errors were reported, we calculated the
standard error from the CIs. Where neither were pro-
vided, we calculated the standard error using the standard
formula for the standard error for a proportion using the
raw data (i.e. the numerator and denominator).
Meta-analyses
A random effects meta-analysis using the inverse vari-
ance method [9] was conducted to provide an overall
estimate of coverage where seven or more data points
were available for the same vaccine type, age group and
time period (i.e. the time period subsequent to the intro-
duction of universal funding for that vaccine in the
population group under examination). Estimates of
coverage and summary estimates for studies included in
the meta-analyses were then presented in forest plots for
each vaccine. The results were reported as vaccinated
proportion with 95 % confidence intervals. Analyses
were conducted using STATA version 12.1.
Ethics
This study was approved by the University of New South
Wales Human Research Ethics Panel (Social/Health
Research) (9-14-12).
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Results
The initial search strategy retrieved a total of 219 titles
and abstracts, of which 45 were duplicates. After screening
the titles and abstracts, the full texts of 44 reports were re-
trieved of which 22 (including 15 peer-reviewed and seven
non-peer reviewed reports) met the inclusion criteria for
the review (see Fig. 1). Of those reports retrieved but not
included, ten studies did not report vaccination coverage,
four studies investigated an intervention and did not
report coverage, four reported coverage only for a specific
population sub-group, three reported only on vaccine effi-
cacy or safety, and one paper reported on a subset of data
from one of the reports included.
Summary of included studies
Table 1 provides a summary of the characteristics of
each included study. Twenty-one studies were cross-
sectional and one was a case-cohort design [10]. The
number of participants ranged from 50 to 15836 (me-
dian = 5590, interquartile range (IQR) 1462 to 10231).
The age ranges sampled varied considerably. Twelve
studies collected data from people aged ≥18 years, five
from people aged ≥15 years (one of these included chil-
dren as well), two from people aged ≥40 years, two from
people aged ≥65 years and one from people aged
≥60 years. Within each study, vaccination coverage was
reported for a variety of different age groups and some
studies, such as the NSW Ministry of Health reports
[11], included separate measures of coverage for many
individual years in unique population samples. Hence
there were substantially more point estimates of vaccin-
ation coverage than the number of included studies.
Coverage estimates in Tables (Tables 2, 3, and 4) are
therefore listed by both the study name and the year of
reported coverage.
Of the 22 studies, 11 sampled Australia-wide (one of
which looked specifically at the Aboriginal and Torres
Strait Islander population) [3, 12–21], three focused
specifically on Aboriginal and Torres Strait Islander adults
in far north Queensland [22–24], three focused on
Victoria [10, 25, 26], the remaining two focused on NSW
[11] and Queensland [27] respectively and two were based
on estimates from a single hospital [10, 28, 29]. The most
common (n = 10; [3, 11–15, 19, 25, 27, 30]) methodology
was to ascertain vaccination coverage using self-reported
vaccination status obtained through interviews conducted
after random-digit dialling potential participants; 4 smaller
studies used self-report from face-to-face interviews and 5
used provider reported vaccination status [10, 16–18, 26].
Three studies described coverage using records extracted
from state-based vaccination databases, which rely on
health care providers reporting vaccination to the register
[22–24]. Seven studies reported on vaccination coverage
specifically in Aboriginal and Torres Strait Islander people
[15, 20–24]. For 16 studies the primary aim was to obtain
information on vaccination [3, 10, 12–15, 19, 22–30]
whilst for six others, data on vaccination was collected as
part of a larger health survey [11, 16–18, 20, 21].
Influenza vaccination coverage
A total of 18 studies identified reported annual influenza
vaccination coverage in the general adult population
aged ≥18 years (see Table 2), with 16 (88.9 %) including
coverage data specifically in those aged ≥65 years. From
these studies a total of 63 point estimates covering years
from 1992 to 2013 were extracted.
Estimated coverage in those aged ≥65 years ranged from
44.4 to 82.4 % over the whole period examined, 1990–2015
(Table 2). Reported coverage prior to the introduction of
funded vaccination in 1999 ranged from 44.4 to 71.3 %
with coverage following 1999 ranging from 63.9 to 82.4 %.
Coverage following 1999 was significantly higher than that
prior to 1999 (p > 0.001); the summary coverage estimate
prior to 1999 from 10 data points was 61.3 % (95 % CI
58.0–64.6 %); versus 74.8 % (95 % CI 73.4–76.2 %); from
1999 onwards from 27 data points.
There was significant heterogeneity in the estimates of
influenza vaccine coverage in those aged ≥65 years from
1999 onwards (I2 = 94.1 %, p < 0.001) and also among the
estimates prior to 1999 (I2 = 93.9 %, p < 0.001) ((Fig. 2). To
explore this in the data collected from 1999 onwards, we
examined the data in subgroups based on location (NSW
or Australia-wide; Appendix). For data collected in NSW
(11 data points) the summary estimate of coverage was
73.5 % (95 % CI 72–74 %); I2 = 94.0 %, p < 0.001 while for
data collected Australia-wide (7 data points) the summary
estimate of coverage was 76.4 % (95 % CI 73–79 %); I2 =
Fig. 1 Flow diagram of search strategy results- description. This
figure shows the number of studies included and excluded at each
stage of the review process
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Table 1 Summary of included studies
Article ID Vaccine type Time period
study conducted
Year coverage
reported for
Participants
age (years)
Sample
size
Study
design
Sampling frame Data collection
method
MacIntyre
R, 1993
[25]
Influenza May–June 1992 1992 0+ 537 Cross
sectional
Systematic sampling from
Victorian White Pages
Telephone interviews;
self-report
Hanna,
2001 [23]
Influenza and
pneumococcal
1995–2000 Influenza 1995–2000 15+ 15836 Cross
sectional
All data for Indigenous
adults extracted for Far
North Queensland region
from health department
database (VIVAS database)
Provider reported to
health department
databasePneumococcal
1995–2000
Taylor,
2001 [3]
Influenza and
pneumococcal
1998–2000 Influenza annually
1998, 1999, 2000
18+ 10505 Cross
sectional
Systematic sampling from
the Australia wide White
Pages
Telephone interviews;
self-report
Pneumococcal
1996–2000
Andrews,
2005_V
[26]
Pneumococcal July–Aug 2000 1999 and 2000 65+ 278 Cross
sectional
Participants from the 1999
Victorian Population Health
Survey who agreed to be
contacted for further studies
were sampled. Contacted by
phone for permission and
details before contacting
provider
Telephone interviews;
provider report
Gill, 2007
[30]
Influenza 1993–2004 Reported annually
for each year of study
15+ 8448 Cross
sectional
Not reported Telephone interviews;
self-report
Horby,
2005 [19]
Influenza Oct–Nov 2001 2001 40+ 7681 Cross
sectional
RDD* from Australia wide
White Pages
Telephone interviews;
self-report
Hanna,
2003 [24]
Influenza 2001 2002 15+ 11062 Cross
sectional
All data for Indigenous adults
extracted for Far North
Queensland region from
health department database
(VIVAS database)
Provider reported to
health department
database
Menzies,
2004 [21]
Influenza and
pneumococcal
2001 Influenza 2001
Pneumococcal
1997–2001
18+ 3681 Cross
sectional
National Health Survey- 3
stage random community
sample –Australia wide-
for Indigenous adults
Face to face
interviews; self-report
Andrews,
2005 [10]
Influenza and
pneumococcal
Apr 2000–Mar
2002
Influenza 2000
and 2001
65+ 2934 Case
cohort
Random sample from 2
Victorian hospitals. End of
each month participants
randomly selected from
those discharged in that
month.
Telephone interviews;
provider report
Pneumococcal
2000 and 2001
NSW
Health,
1997–2012
[11]
Influenza and
pneumococcal
2002–2012 Reported each
year of study.
18+ 3416 Cross
sectional
RDD* from NSW White
pages- mobile number’s
included from 2012
Telephone interviews;
self-report
Influenza annually
Pneumococcal
<5 years
AIHW,
2003 [12]
Influenza 2002 Influenza 2002
Pneumococcal
1998–2002
40+ 8000 Cross
sectional
RDD*, Australia wide Telephone interviews;
self-report
Hanna,
2004 [22]
Influenza 2003 2003 15+ 11204 Cross
sectional
All data for Indigenous
adults extracted for Far
North Queensland region
from health department
database (VIVAS database)
Provider reported to
health department
database
AIHW,
2005 [13]
Influenza and
pneumococcal
2004 Influenza 2004
Pneumococcal
2000–2004
18+ 7500 Cross
sectional
RDD*, Australia wide Telephone interviews
Menzies,
2008 [20]
Influenza and
pneumococcal
2004–2005 Influenza 2004/2005 18+ 10439 Cross
sectional
RDD*, Australia wide for
Indigenous adults
Face to face
interviews
Pneumococcal
2001–2005
AIHW,
2008 [14]
Influenza and
pneumococcal
2006 Influenza 2006
Pneumococcal
2002–2006
18+ 8022 Cross
sectional
RDD*, Australia wide Telephone interviews;
self-report
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96.6 %, p < 0.001. The test for heterogeneity between NSW
and Australia-wide estimates was significant; p = 0.03.
There were 9 studies which reported influenza vaccin-
ation coverage specifically in people identified as having
a chronic disease that made them more susceptible to
influenza and its complications [3, 12–15, 17–19, 27]
(Table 2). Between 2000 and 2013, vaccination coverage
estimates for adults aged <65 years with chronic diseases
ranged from 29.8 to 49.2 %; after 2010 when funding
was introduced to target this group, two studies esti-
mated vaccination coverage of 44.7 and 49.2 %. In adults
aged ≥65 years with chronic diseases, coverage was sub-
stantially higher, ranging from 78.5 to 81.7 %.
Pneumococcal vaccine coverage
Eleven studies were identified that reported pneumococcal
vaccination coverage in adults aged ≥18 years (Table 3).
From these studies a total of 41 point estimates covering
years from 1996 to 2013 were extracted. Among studies
reporting vaccination coverage in those aged ≥65 years,
estimates ranged from 15.4 to 72.8 %. Among studies
reporting vaccination coverage for those aged <65 years,
Table 1 Summary of included studies (Continued)
Ridda,
2008 [28]
Influenza and
pneumococcal
June-Nov 2006 Reported ever
vaccinated
previously
60+ 200 Cross
sectional
Convenience sampling
of consecutive inpatients
from one Sydney hospital-
validated with medical
records-
Face to face
interview; self-report
Dower,
2011 [27]
Influenza and
pneumococcal
2008 Influenza 2008 18+ 2203 Cross
sectional
RDD*, Queensland Telephone interviews;
self-report
Pneumococcal
2004–2008
AIHW,
2011 [15]
Influenza and
pneumococcal
2009 Influenza 2009
Pneumococcal
2005–2009
18+ 10231 Cross
sectional
RDD*, Australia wide Telephone interviews;
self-report
Loke, 2012
[29]
Influenza and
pneumococcal
April–May 2011 Influenza annually
2010, 2011
18+ 50 Cross
sectional
Convenience sampling
of random selection of
inpatients from a South
Australian hospital
Face to face
interview; self-report
Pneumococcal ever
vaccinated
BEACH
2014 [16]
Pneumococcal 2013 2009–2013 15+ 2523 Cross
sectional
Random sample of 125
GP practices- Australia
wide –Sample initially
source all GPs who claimed
a min 375 GP A1 Medicare
items. Randomly selected
GPs are then approached
by letter then phone.
Provider reported
from GP records
Cheng,
2013 [17]
Influenza 2012 2012 18+ 1216 Cross
sectional
National hospital based
sentinel surveillance- Australia
wide. Hospitals recruited
from physician members of
the Thoracic Society of
Australia and New Zealand
Pandemic (H1N1) 2009 Task
Force and representatives
of the Australasian Society
for Infectious Diseases. Also
recruited 2 non-urban
hospitals to increase
sample of Indigenous
patients.
Standard collection
instrument, collected
clinical, radiological
and laboratory data-
self report, or medical
record (generally
based on self-report)
Cheng,
2014 [18]
Influenza 2013 2013 18+ 964 Cross
sectional
National hospital based
sentinel surveillance- Australia
wide. Hospitals recruited from
physician members of the
Thoracic Society of Australia
and New Zealand Pandemic
(H1N1) 2009 Task Force
and representatives of the
Australasian Society for
Infectious Diseases. Also
recruited 2 non-urban
hospitals to increase
sample of Indigenous
patients.
Standard collection
instrument, collected
clinical, radiological
and laboratory data-
self report, or medical
record (generally
based on self-report)
*RDD random digit dialling
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Table 2 Annual influenza vaccination coverage by age group and year
Study ID Year influenza vaccine given Estimated coverage (%) Number vaccinated/Total population
Age ≥65 years
MacIntyre 1993 [25] 1992 44.4 43/97
Gill 2007 [30] 1993 55.6 265/477
Gill 2007 [30] 1994 55.5 282/508
Gill 2007 [30] 1995 62.3 320/514
Gill 2007 [30] 1996 67.1 349/520
Gill 2007 [30] 1997 67.7 773/1141
NSW Ministry of Health 1997 [11] 1997 56.0 1840/3283
Gill 2007 [30] 1998 71.3 829/1163
Taylor, 2001 [3] 1998 60.7 4389/7228
NSW Ministry of Health 1998 [11] 1998 63.8 2169/3401
Gill 2007 [30] 1999 77.1 897/1163
Taylor, 2001 [3] 1999 69.8 5047/7228
Andrews, 2005_V [26] 1999 72.3 N/A
Gill 2007 [30] 2000 80.3 846/1054
Taylor, 2001 [3] 2000 74.1 5357/7228
Andrews, 2005 [10] 2000 78.4 N/A
Gill 2007 [30] 2001 79.8 451/565
Horby 2005 [19] 2001 78 N/A
Andrews, 2005 [10] 2000 67.4 1978a/2934
Andrews, 2005 [10] 2001 74.5 2186a/2934
NSW Ministry of Health 2002 [11] 2002 75.6 2549/3419
AIHW 2003 [12] 2002 76.9 NA
Gill 2007 [30] 2002 80.1 306/382
NSW Ministry of Health 2003 [11] 2003 75.5 2692/3577
Gill 2007 [30] 2003 81.2 310/382
Gill 2007 [30] 2004 82.4 477/579
AIHW 2005 [13] 2004 79.1 4067a/5141
NSW Ministry of Health 2004 [11] 2004 75.4 2022/2706
NSW Ministry of Health 2005 [11] 2005 74.7 2508/3390
NSW Ministry of Health 2006 [11] 2006 75.1 1744/2388
AIHW 2008 [14] 2006 77.5 4356a/5621
NSW Ministry of Health 2007 [11] 2007 72.3 1698/2347
NSW Ministry of Health 2008 [11] 2008 71.4 1935/2742
NSW Ministry of Health 2009 [11] 2009 72.3 2537/3561
AIHW, 2011 [15] 2009 74.6 3959a/5307
NSW Ministry of Health 2010 [11] 2010 72.6 2559/3601
NSW Ministry of Health 2011 [11] 2011 72.4 3470/4749
Loke, 2012 [22] 2011 63.9 23/36
NSW Ministry of Health 2012 [11] 2012 68.4 2799/4030
Cheng 2013 [17] 2012 77.6 420/541
Cheng 2014 [18] 2013 80.5 178/221
Age <65 years
Horby, 2005 [19] 2001 24.0 N/A
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estimates ranged from 4.8 to 33.9 % but the age ranges
sampled were inconsistent with some reporting from adults
aged ≥18 and some from age ≥50 years. There were also
differences in the time period for reported pneumococcal
vaccination, with some studies reporting pneumococcal
vaccine received within the previous year and others report-
ing within the previous 5 years (see Table 3).
Among adults aged ≥65 years, in 5 studies conducted
prior to 2005 [3, 10, 11, 13, 26], the proportion reporting
pneumococcal vaccination in the last 5 years ranged from
15.4 to 57.9 %; in 7 studies conducted from 2005 onwards
it ranged from 50.3 to 72.8 % [11, 14–16, 27–29]. Cover-
age from 2005 onwards was significantly (p = 0.02) higher
than that prior to 2005; the summary coverage estimate
prior to 2005 from 4 data points was 35.4 % (95 % CI
18.8–52.0 %) versus 56.0 % (95 % CI 53.2 %–58.8 %) from
2005 (10 data points) (Fig. 3). Eight of the data points for
pneumococcal coverage after 2005 came from one study
[11]. As with influenza, there was significant heterogeneity
in the summary estimates of coverage both prior and after
universal funding (p < 0.001 for both; Fig. 3).
Influenza and pneumococcal vaccine coverage in
Aboriginal and Torres Strait Islander Australians
Seven studies reported influenza and/or pneumococcal
vaccination coverage in Aboriginal and Torres Strait Is-
lander adults [15, 20–24] (Table 4). The recommendations
and funding for influenza vaccination of Aboriginal adults
were extended to include all those aged ≥15 years in 2010.
All studies that met our inclusion criteria were conducted
prior to 2010. Sample sizes ranged from 10 to 15836 with
coverage reported for a number of different age groups.
Four of the studies were Australia-wide, while the other
three were based in far north Queensland. Among studies
reporting influenza vaccination coverage, two studies esti-
mated coverage of 85 % in those aged 15–49 years [22,
24], one study estimated coverage of 23 % in those aged
18–49 years [20], one study estimated coverage of 27.5 %
in those aged ≥18 years [15]. In those aged ≥50 years
coverage estimates ranged from 51 to 96 % (4 estimates)
[21, 22, 24] and in those aged ≥65 years the available esti-
mates ranged from 71 % to 89 % [20, 21]. For pneumococ-
cal vaccination coverage, 2 estimates for those aged 50–
Table 2 Annual influenza vaccination coverage by age group and year (Continued)
AIHW 2003 [12] 2002 18.6 N/A
AIHW 2005 [13] 2004 18.8 N/A
AIHW 2008 [14] 2006 20.2 485a/2401
Ridda, 2007 [17] 2006 63.6 124/195a
AIHW, 2011 [15] 2009 22.8 3200/14035a
AIHW, 2011 [15] 2009 36.2 NA
Loke, 2012 [29] 2011 21.4 3/14
Cheng 2013 [17] 2012 40.0 270/675
Cheng 2014 [18] 2013 49.2 92/187
Age ≥65 years with risk factors
Dower, 2011 [27] 2008 81.7 594/727a
Cheng 2013 [17] 2012 78.5 397/506
Cheng 2014 [18] 2013 80.4 172/214
Age <65 years with risk factors
Taylor 2001 [3] 2000 32.2 367/NA
Horby 2005 [19] 2001 34.0 N/A
AIHW 2003 [12] 2002 41.7 N/A
AIHW 2005 [13] 2004 41.6 N/A
AIHW 2008 [14] 2006 29.8 N/A
Dower, 2011 [27] 2008 46.5 345/742a
AIHW, 2011 [15] 2009 36.2 N/A
Cheng 2013 [17] 2012 44.7 238/532
Cheng 2014 [18] 2013 49.2 92/187
N/A not available; data not available from estimates provided or contacting authors
araw numbers calculated by authors as not provided in study
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Table 3 Pneumococcal vaccination by age group and year
Study ID Year/s pneumococcal vaccine given Estimated coverage (%) Number vaccinated/Total population
Age ≥65 years
Andrews, 2005 [10] 1996–2000 57.9 N/A
Taylor, 2001 [3] 1996–2000 15.4 991/6435a
Andrews, 2005 [10] 1997–2001 49.1 NA
Andrews, 2005 [10] 1998–2002 56.3 NA
NSW Ministry of Health 2002 [11] 1998–2002 37.8 1294/3419
NSW Ministry of Health 2003 [11] 1999–2003 45.2 1617/3577
NSW Ministry of Health 2004 [11] 2000–2004 43.2 1169/2706
AIHW 2005 [13] 2000–2004 51.1 N/A
NSW Ministry of Health 2005 [11] 2001–2005 51.9 1759/3390
NSW Ministry of Health 2006 [11] 2002–2006 58.0 1385/2388
Ridda, 2007 [28] 2006 50.3 98/195a
AIHW 2008 [14] 2002–2006 62.2 NA
NSW Ministry of Health 2007 [11] 2003–2007 56.8 1332/2347
NSW Ministry of Health 2008 [11] 2004–2008 56.2 1541/2742
Dower, 2011 [27] 2008 67.6 498/737
NSW Ministry of Health 2009 [11] 2005–2009 53.4 1900/3561
AIHW 2011 [15] 2005–2009 54.4 2679a/4924
NSW Ministry of Health 2010 [11] 2006–2010 51.2 1844/3601
NSW Ministry of Health 2011 [11] 2007–2011 56.1 2664/4749
Loke 2012 [29] 2011 54.1 20/37
NSW Ministry of Health 2012 [11] 2008–2012 50.5 2036/4030
BEACH 2014 [16] 2009–2013 72.8 685a/941
Age <65 years
NSW Ministry of Health 2002 [11] 1998–2002 6.4 229/3501
NSW Ministry of Health 2003 [11] 1999–2003 6.6 236/3568
NSW Ministry of Health 2004 [11] 2000–2004 8.0 227/2838
NSW Ministry of Health 2005 [11] 2001–2005 9.2 313/3403
AIHW 2008 [14] 2002–2006 6.5 N/A
NSW Ministry of Health 2006 [11] 2002–2006 10.3 246/2381
NSW Ministry of Health 2007 [11] 2003–2007 10.3 243/2348
NSW Ministry of Health 2008 [11] 2004–2008 10.8 296/2731
Dower 2011 [27] 2008 25.6 181/707a
Dower 2011 [27] 2008 11.04 58/525a
AIHW 2011 [15] 2005–2009 4.8 258a/5307
NSW Ministry of Health 2009 [11] 2005–2009 10.1 351/3489
NSW Ministry of Health 2010 [11] 2006–2010 11.1 383/3458
Loke 2012 [29] 2011 23.1 3/13
NSW Ministry of Health 2011 [11] 2007–2011 13.4 588/4399
NSW Ministry of Health 2012 [11] 2008–2012 10.9 448/4126
BEACH 2014 [16] 2009–2013 33.9 a809/2386
Age <65 years with risk factors
Taylor 2001 [3] 2000 3.5 39/1114a
BEACH 2014 [16] 2009–2013 57.9 770/1330
N/A not available
araw numbers calculated by authors as not provided in study
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64 years were available, reporting 20 and 30 %. Similarly,
there were 2 pneumococcal estimates available for those
aged ≥65 years, reporting 47 and 48 % [20, 21].
Factors associated with receipt of vaccination
Seven studies reported on individual characteristics and
other factors associated with receiving vaccination among
adults [3, 19, 25, 27–30]. The majority reported on factors
associated with influenza vaccination [3, 19, 25, 29, 30],
however two studies reported factors associated with both
influenza and pneumococcal vaccination [27, 28]. All
studies used a cross-sectional design and an interviewer-
administered questionnaire (either by phone or in person).
The most important predictor of vaccination was being
aged ≥65 versus <65 years, with a statistically significant
association found in five studies [3, 25, 27–29]. All other
studies that reported influenza vaccination by age showed
a higher point estimate of coverage in the older age group
although no statistical tests were described.
After adjusting for age, a number of factors were
consistently reported to be significantly associated with
vaccination. Two studies reported a statistically signifi-
cant association between lower education (versus higher
education level) and greater likelihood of vaccination
with adjusted odds ratios ranging from 1.12 (95 % CI
1.01–1.21) to 1.5 (95 % CI 1.1–1.9) [3, 19]. Two studies
reported statistically significant associations between
lower income (versus higher income) and vaccination
with adjusted odds ratios ranging from 1.4 (95 % CI 1.1–
2.3) to 2.96 (95 % CI 1.59–5.52) (3, 19). Having a med-
ical risk factor, being female, living in a metropolitan
area, having a positive perception of vaccination, doctor
recommending influenza vaccination to the patient, hav-
ing poor self-reported health status and believing the
Table 4 Influenza and/or pneumococcal vaccination in Aboriginal and/or Torres Strait Islander Australians by age range and time period
Disease Study ID Year/s vaccination given Age range Estimated coverage (%) Number vaccinated/Total population
Influenza
Hanna, 2003 [24] 2001 15–49 85 7719/9081
Hanna, 2004 [22] 2003 15–49 85 7671/9025
Menzies, 2008 [20] 2004–2005 18–49 23 N/A
AIHW 2011 [15] 2009 ≥18 27.5 N/A
Taylor, 2001 [3] 1998 40-64* 9.4 1/10
Taylor, 2001 [3] 1999 40-64* 19.9 3/15
Taylor, 2001 [3] 2000 40-64* 22.5 3/13
Hanna, 2004 [22] 1995–2000 ≥50 96 2582/2690
Hanna, 2003 [24] 2001 ≥50 59.4 3275/5513
Menzies 2004 [21] 2001 ≥50 51 N/A
Hanna, 2004 [22] 2003 ≥50 63 3533/5608
Menzies 2004 [21] 2001 50–64 47 N/A
Menzies, 2008 [20] 2004–2005 50–64 52 N/A
Taylor, 2001 [3] 1998 ≥65 80.1 19/24
Taylor, 2001 [3] 1999 ≥65 89.0 21/24
Taylor, 2001 [3] 2000 ≥65 78.2 19/24
Menzies 2004 [21] 2001 ≥65 71 N/A
Menzies, 2008 [20] 2004–2005 ≥65 84 N/A
Pneumococcal
Hanna, 2001 [23] 1995–2000 15–49 73 3274/NA
Menzies, 2008 [20] 2001–2005 18–49 12 N/A
Hanna, 2001 [24] 1995–2000 ≥50 73 1971/2700
Menzies 2004 [21] 2001 ≥50 25 N/A
Menzies 2004 [21] 2001 50–64 20 N/A
Menzies, 2008 [20] 2001–2005 50–64 30 N/A
Menzies 2004 [21] 2001 ≥65 47 N/A
Menzies, 2008 [20] 2001–2005 ≥65 48 N/A
N/A not available
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vaccine to be effective were each reported to be signifi-
cantly associated with greater likelihood of vaccination
in two studies each [3, 19, 25]. Being a non-smoker [27],
believing the vaccine will not make you ill, having more
correct knowledge [28] and having a positive attitude to-
wards vaccination [28] were all found to be significantly
associated with vaccination in one study each.
In two studies of Aboriginal and Torres Strait Islander
adults, being aged ≥50 versus those aged 18–49 and living
in a remote versus non-remote area were consistently
reported as having greater likelihood of being vaccinated
for influenza and pneumococcal disease although no stat-
istical tests were presented [20, 21].
Discussion
In this review we found 22 studies yielding 81 data
points on influenza and 49 data points on pneumococ-
cal vaccination coverage between 1990 and 2015 for a
general population of adults in Australia. Studies in re-
lation to influenza vaccination ranged over a wider time
period than those for pneumococcal vaccination. The
majority of included studies focused on annual influ-
enza vaccination coverage and used a cross sectional
study design. Random-digit dialling of potential partici-
pants and self-reported vaccination status obtained
through interviews were the commonest methods
employed to ascertain data. A small number of studies
collected data from surveying healthcare providers dir-
ectly about their patients or from a state based immun-
isation database, which requires providers to report
immunisations given. Most studies had sample sizes of
over 1000 participants.
Around three-quarters of adults aged ≥65 years were es-
timated to have received annual influenza vaccination in
the period after 1999. Vaccination coverage was higher
following the introduction of the funded universal vaccin-
ation program for people aged ≥65 years. The current
national immunisation strategy considers the influenza
vaccination coverage in people aged ≥65 years to be rela-
tively low and suggests coverage needs to improve. How-
ever, there are no official national coverage targets for
adults, and no clear plan for improving coverage [31].
Fig. 2 Meta-analysis of eligible studies of influenza vaccination coverage, before and after the introduction of universal funding of vaccine for
adults aged ≥65 years. This figure shows the results from the meta-analysis of studies reporting influenza vaccination coverage, before and after
the introduction of universal funding of vaccine for adults aged ≥65 years
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Coverage estimates were lower in people aged <65 years
with medical risk factors surveyed after 2010, who were
also funded to receive influenza vaccine, compared to
coverage in people aged ≥65 years with risk factors. While
there were only 2 studies that reported on this period and
the sample sizes were relatively small [17, 18], this finding
suggests that factors other than funding are important for
improving vaccination coverage in adults. Universal rec-
ommendations have historically been more successful
with achieving high coverage than targeted recommenda-
tions for risk groups [32], and this is supported by our
findings. This may be due to the fact that universal recom-
mendations are usually easier to implement.
Pneumococcal vaccination coverage also appeared to be
influenced by funding, with a summary estimate of cover-
age in the ≥65 year age group prior to the introduction of
funding in 2005 of 35.4 % (95 % CI 18.8 %–52.0 %). How-
ever even after 2005, coverage estimates for pneumococcal
were lower than that for influenza at around 56 %. This
difference may arise due to a greater awareness of the
availability and need for influenza vaccine. It could also be
that pneumococcal coverage levels are under-reported.
Only one of the identified studies of pneumococcal cover-
age in ≥65 year olds (the ‘Bettering the evaluation and care
of health’ (BEACH) study [16]) relied on provider report,
as opposed to self- reported vaccination status. Coverage
reported from this study was substantially higher at
72.8 % and more comparable to that for influenza in
≥65 year olds. Recall bias may affect both self-report for
pneumococcal and influenza vaccination, but could possibly
be less for influenza as it is given annually. The higher
coverage reported in the BEACH study may also have been
affected by the sample, which is not population-based, and
only includes people who attend GPs.
All of the available data on influenza and pneumococ-
cal vaccination coverage in Aboriginal and Torres Strait
Islander adults comes from studies that were conducted
prior to 2010 when funding for influenza vaccination of
Aboriginal and Torres Strait Islander adults was limited
to adults aged ≥50 years and adults aged <50 years with
risk factors [4]. Influenza vaccination coverage reported
in Aboriginal and Torres Strait Islander adults aged
≥65 years appeared to be similar to the general Austra-
lian adult population of the same age. Two of the three
studies which reported on influenza vaccination cover-
age in Aboriginal and Torres Strait Islander adults for
this age group had large samples of Aboriginal and
Torres Strait Islander adults and included sampling and
recruitment in remote areas, making it likely the find-
ings are robust and generalisable. Lack of data in con-
sistent age groups or time periods makes it difficult to
make comparisons of pneumococcal vaccination cover-
age in Aboriginal and Torres Strait Islanders and the
general Australian adult population.
In both meta-analyses of influenza and pneumococcal
vaccination coverage in ≥65 year olds we found signifi-
cant heterogeneity. The large sample sizes of most stud-
ies is likely to have contributed to this, by making small
Fig. 3 Meta-analysis of eligible studies of pneumococcal vaccination coverage before and after the introduction of universal funding of vaccine
for adults aged ≥65 years. This figure shows the results from the meta-analysis of studies reporting pneumococcal vaccination coverage, before
and after the introduction of universal funding of vaccine for adults aged ≥65 years
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differences in coverage statistically significant. Despite this,
we attempted to explore possible reasons for this hetero-
geneity. When data for NSW influenza coverage among
adults were combined and compared to a combined esti-
mate for Australia-wide coverage we found a significantly
higher estimate for national coverage; it is unclear what the
reasons may be for this. Another possible source of hetero-
geneity was differences in data collection methods (e.g. self-
report vs provider report vs state based databases), however
there were too few data points from studies using provider
report and state-based databases to make reliable compari-
sons. The most effective and accurate methods of data
collection requires further exploration, particularly to help
inform the development of the recently announced whole-
of-life vaccination register in Australia.
Comparing coverage reported in this systematic review
for Australia to other high income countries with funded
vaccination programs, there were some similarities and dif-
ferences. Data from England for 2014/2015 showed influ-
enza vaccination coverage of 72.7 % in those aged ≥65 years
[33]. For the same time period influenza vaccination cover-
age in those aged <65 years with risk factors appeared to be
slightly higher in England (50.3 %) [33] compared to the es-
timates we found for Australia. In both countries both
groups are funded for free influenza vaccination [33]. In the
United States (US) reported influenza coverage in 2014/
2015 was slightly lower than the Australian estimates for
people aged ≥65 years at 66.7 %. Coverage for those aged
<65 years with risk factors in the US, was more similar to
the Australian coverage reported at 47.6 % [34]. Compared
to the United Kingdom (UK) and the US, the pneumococ-
cal vaccination coverage reported from Australian studies
among those aged ≥65 years appeared somewhat lower; in
2015 in England coverage was 69.8 % [35] and in the US in
2013 it was 59.7 % [36]. However, these percentages are
‘ever received’ pneumococcal vaccination compared to the
Australian coverage presented in this paper which generally
reports on receipt of vaccine in the previous 5 years.
There were few studies reporting on factors other than
age associated with influenza or pneumococcal vaccination
status. Of all the factors reported to be consistently associ-
ated with vaccination in this review of Australian data
(lower education, lower income, a medical risk factor, being
female, living in a metropolitan area, having a positive per-
ception of vaccination, doctor recommending influenza
vaccination to the patient, having poor self-reported health
status and believing the vaccine to be effective), each has
also been found to be significantly associated with influenza
vaccination internationally [37–44]. However, some studies
from other countries report variable relationships with sex
and education [40]. Given the small number of studies,
however, more information regarding factors associated
with vaccination in Australia would assist in better targeting
of vaccination programs. The findings in relation to lower
education and lower income have implications for future
interventions and further investigation into this issue would
be of benefit.
To our knowledge, this is the first systematic review of
adult vaccination coverage in Australia. Limitations include
that coverage was not always reported in consistent age
groups and/or the raw data were not available. This re-
stricted the number of studies that could be included in
the meta-analysis. Also, many reports of coverage are
found in the grey literature rather than easily searchable
electronic databases, which means that there is a possibility
that some sources were missed. However, we minimised
this by consulting with experts. A majority of studies relied
on self-reported data. Self-reported influenza and pneumo-
coccal vaccination status have been shown to be highly
sensitive, but less specific [45–47] which may mean that
studies using self-report are over-reporting coverage. To
date there has been little work carried out to validate pro-
vider report or the state-based databases which were used
by other studies to obtain coverage estimates although it is
likely that these sources would underestimate coverage due
to vaccinations occurring in different sites or providers not
reporting to the state-based databases. It may be that this
difference underlies the heterogeneity in coverage reports
we found for pneumococcal vaccination in those ≥65 years.
Quantifying the accuracy of different data sources for
estimating adult vaccine coverage is an important area for
future research.
The higher level of both influenza and pneumococcal
vaccination coverage in people aged ≥65 years in Australia
since funding for each vaccine was introduced suggests
that programs that cover vaccine costs can increase adult
vaccination coverage. However, other factors are also likely
to play a part, as pneumococcal vaccine coverage after
2005 appeared to be lower than influenza in the ≥65 year
age group despite both vaccines being funded. This may be
due to the increased complexity of the pneumococcal
schedule, and lack of confidence in the vaccine due to lim-
ited evidence supporting its effectiveness in adults [48]. In
addition, influenza vaccination coverage in people aged
<65 years with risk factors, which were also funded after
2010, had much lower vaccination coverage than those in
the universally funded group (≥65 years). These findings
suggest that whilst funding is important, the way in which
funding is provided can also impact. It also highlights the
complex nature of adult vaccination and the challenges in
obtaining high vaccine coverage in some populations.
Lower coverage is often found in targeted programs due to
the increased complexity, difficulty in identifying patients
and being aware of eligibility [49]. There is some evidence
that adult vaccination coverage in funded groups can be
increased when combined with other strategies aimed
at primary care providers. Some strategies which have
shown success include identifying one key staff member in
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a practice to plan and lead an influenza campaign [50],
educational outreach aimed at primary care [50], patient
tracking and provider prompts [51].
We found no evidence that Aboriginal and Torres
Strait Islander adults aged ≥65 years had substantially
different annual influenza coverage than the general
population of adults ≥65 years. However, this was based
on findings from 3 studies from early last decade [20,
21]. There were also variations in the estimates of cover-
age provided for Aboriginal and Torres Strait Islander
adults, making comparisons difficult. Given the in-
creased vulnerability of Aboriginal and Torres Strait Is-
lander adults to respiratory illnesses such as influenza
and pneumococcal disease [52] and specific programs
targeting these adults, more current and detailed data
on vaccination coverage in this group is warranted.
Conclusions
We found that although the majority of adults in the gen-
eral population aged ≥65 years are receiving vaccination
for influenza and for pneumococcal diseases, coverage is
much lower than that for childhood vaccines. In people
aged <65 years with co-morbidities, who are at higher risk
of influenza than those without, vaccine coverage is sub-
stantially lower than in those aged ≥65 years, despite this
group being funded for free vaccines since 2010. This find-
ing supports suggestions [32] that targeted vaccine pro-
grams are less effective at achieving high coverage. Official
national vaccination coverage targets for the adult popula-
tion and programmatic measures to improve overall
coverage would be useful. Such measures may include
incentives and key performance indicators. This review
also highlights the limited sources of information currently
available in relation to adult vaccination coverage in
Australia, especially in relation to Aboriginal and Torres
Strait Islander adults. More data are required to provide
better estimates of coverage in this higher risk group and
also to identify other groups of adults in whom vaccination
coverage could be improved. Given the recent announce-
ment by the federal government to implement a whole-of-
life immunisation register in Australia, identifying an ef-
fective and efficient methodology to collect accurate data
on adult immunisation coverage, especially for the subjects
of targeted programs, such as Aboriginal and Torres Strait
Islander adults and people with medical risk factors, will
be an important priority.
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Fig. 4 Meta-analysis of eligible studies of influenza vaccination coverage from 1999 for adults aged ≥65 years, by location (National versus NSW).
This appendix figure shows the results from the meta-analysis of studies reporting influenza vaccination coverage post introduction of funding by
location in people aged ≥65 years
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